Tradestie Institutional Equity Comparison Engine

REGN vs ALNY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

REGN Overall Edge

REGN Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while ALNY counters with relative strength in Valuation. Fundamentally, REGN trades at 14.9x Forward P/E with 30.4% operating margin (+36.3% YoY revenue) versus ALNY at 15.0x Forward P/E and 19.5% operating margin (+16.7% YoY). In options structure, REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against ALNY sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ALNY
REGN 14.9x vs ALNY 15.0x Fwd P/E
Growth & Margin Winner REGN
Op Margin 30.4% vs 19.5% ยท YoY +36.3% vs +16.7%
Momentum & Technical Winner REGN
1Y +27.3% vs -68.0% ยท 52W Pos 83% vs 0%
Options & Structure Winner REGN
CONSOLIDATION (6th %ile IV) vs BREAKDOWN (34th %ile IV)
REGN NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$923.34
-2.35% 1D
Market Cap $97.8B
1M Return +14.61%
1Y Return +27.3%
Forward P/E 14.9x
Unified AI Score
42.6 / 100 HOLD
Tech 19.0 Fund 45.0 Flow 68.0 Mom 56.0
ALNY NASDAQ
Alnylam Pharmaceuticals, Inc.
Pharmaceutical Preparations
$147.82
-1.06% 1D
Market Cap $20.0B
1M Return -34.33%
1Y Return -68.03%
Forward P/E 15.0x
Unified AI Score
50.9 / 100 HOLD
Tech 45.0 Fund 64.0 Flow 67.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: REGN +27.3% ALNY -68.03% Spread: +95.33 pp (REGN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period REGN Revenue ALNY Revenue REGN Op. Margin ALNY Op. Margin Margin Edge
FY2018 $5.15B $70M 49.3% -1087.6% REGN
FY2019 $6.56B $220M 33.7% -427.5% REGN
FY2020 $8.50B $490M 42.1% -168.1% REGN
FY2021 $16.1B $840M 55.7% -83.9% REGN
FY2022 $12.2B $1.04B 38.9% -75.7% REGN
FY2023 $13.1B $1.83B 30.9% -15.4% REGN
FY2024 $14.2B $2.25B 28.1% -7.9% REGN
FY2025 $14.3B $3.71B 24.9% 13.5% REGN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: REGN (6) vs ALNY (4)
Institutional Metric REGN ALNY Criterion Row Winner
Market Capitalization Scale $97.8B $20.0B Larger Scale REGN
Trailing P/E Ratio Valuation 20.9x 7.5x Lower Multiple ALNY
Forward P/E Ratio Valuation 14.9x 15.0x Lower Multiple REGN
Revenue Growth (YoY) Growth +36.3% +16.7% Higher Growth REGN
Operating Margin (TTM) Profitability 30.4% 19.5% Higher Margin REGN
Net Profit Margin Profitability 28.5% 52.8% Higher Margin ALNY
Return on Equity (ROE) Capital Efficiency 14.9% 138.1% Higher ROE ALNY
52-Week Range Position Momentum 83% ($592โ€“$992) 0% ($147โ€“$477) Stronger Trend REGN
Beta / 30D Volatility Risk Regime 0.32ฮฒ ยท 55% Vol 0.55ฮฒ ยท 94% Vol Lower Realized Risk REGN
Unified Institutional Score Composite Signal 42.6 / 100 (HOLD) 50.9 / 100 (HOLD) Higher Composite ALNY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full REGN vs ALNY Buy Guide
REGN CONSOLIDATION
55d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live REGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ALNY BREAKDOWN
55d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 34th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ALNY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither REGN nor ALNY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.